Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial

doi:10.1182/blood-2021-150145

	Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
	Ding, Kaiyang 1; Liu, Hailing 2,3; Yang, Haiyan 4; Cao, Lei 2,3; Zhao, Xiaoli 3; Wu, Wei 2,3; Zhang, Xiaoyan 2,3; Wang, Li 2,3; Xu, Wei 2,3; Zhu, Huayuan 2,3
刊名	BLOOD
	2021-11-23
卷号	138
ISSN号	0006-4971
DOI	10.1182/blood-2021-150145
WOS研究方向	Hematology
语种	英语
出版者	AMER SOC HEMATOLOGY
WOS记录号	WOS:000736398805113
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/131812]
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Hosp, Dept Hematol, Hefei, Peoples R China 2.Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Hematol, Hefei, Peoples R China 3.Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Ding, Kaiyang,Liu, Hailing,Yang, Haiyan,et al. Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial[J]. BLOOD,2021,138.
APA	Ding, Kaiyang.,Liu, Hailing.,Yang, Haiyan.,Cao, Lei.,Zhao, Xiaoli.,...&Fan, Lei.(2021).Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial.BLOOD,138.
MLA	Ding, Kaiyang,et al."Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial".BLOOD 138(2021).